$TWST

Green Paula sold $62K of TWST

Green Paula (SVP of Human Resources) sold 884 shares of Twist Bioscience Corp (TWST) at $69.84 on 2026-06-08.

Original reporting
SEC EDGAR · Green Paula
Published Jun 10, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure updates the insider ownership record and may marginally influence sentiment, but it does not introduce new operational, financial, or regulatory information.

02

Market read

Company-specific insider selling disclosure; generally low trading impact absent additional fundamental catalysts.

03

What to watch

Insider sales often reflect diversification, taxes, or pre-planned liquidity needs; the article provides no rationale or follow-on buying.

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-10 for a sale executed 2026-06-08

Background

The article is a primary SEC Form 4 insider transaction disclosure for Twist Bioscience.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience disclosed an insider open-market sale: SVP of Human Resources Green Paula sold 884 shares at $69.8442 on 2026-06-08 via Form 4.

Expected impact

Likely limited/short-lived impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is primary-source and company-specific, but the transaction is modest in size and is an open-market sale by an HR SVP, not a buy or a large block tied to a corporate event.

Market effects

No clear read-across to biotech tools/biomanufacturing beyond routine insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly tied to a 10b5-1 plan, some traders may interpret it as a stronger near-term caution signal than typical scheduled selling.

Key entities

  • Twist Bioscience Corp

    Company whose insider transaction was reported on SEC Form 4.

  • Green Paula

    SVP of Human Resources who sold 884 shares in an open-market transaction.

Related articles

$TWSTMedAI 8/10

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.

$TWSTMed

Twist Bioscience Q3 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.

$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.

$TWSTHigh

Twist Bioscience Corp (TWST): Results of Operations and Financial Condition

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth

$AMDMedAI 8/10

Cathie Wood Pours $8. 5M Into Cerebras Amid Buzz Around AI Chip Upstart, Wont Stop Dumping AMD - Advanced

According to Benzinga, Cathie Wood’s Ark made a $10.8M purchase of Cerebras shares (42,126) on Friday, while also selling 16,998 shares of Teradyne and buying 2,451 shares of Twist Bioscience via ARKK. Separately, the report notes AMD is ramping Vera Rubin production, but U.S.-China policy and China’s share of net sales remain key factors for investors.